Modern multimodality cancer treatment has led to a rise in cancer survivors, and by 2030 the survival rate is estimated to increase by 31.4%. This is an impressive survival statistic on which clinicians and services continue to build. One of the less well-acknowledged consequences of survivorship among health professionals and patients alike is female sexual dysfunction, despite it occurring in more than 60% of women diagnosed with cancer. The systematic assessment and management of late effects from cancer lack integration within current models of oncology follow-up. Although highly prevalent, issues linked to sexual health are often not addressed among survivors. This overview aims to focus on the sexual impact of gynaecological cancer treatment. Clinicians should raise the topic of the sexual consequences of cancer treatment as a legitimate aspect of survivorship and service provision. Increased focus on the sexual consequences of treatment and cancer survivorship may in time lead to greater clinical recognition, service development and, most importantly, increase research focused on the effective management of what remains a neglected aspect of cancer care.

现代多模式癌症治疗导致癌症幸存者人数增加，预计到 2030 年生存率将提高 31.4%。这是一个令人印象深刻的生存统计数据，临床医生和服务继续在此基础上建立。尽管有超过 60% 的被诊断患有癌症的女性会出现这种情况，但在卫生专业人员和患者中，幸存者中鲜为人知的后果之一是女性性功能障碍。对癌症晚期影响的系统评估和管理缺乏与当前肿瘤学随访模型的整合。虽然非常普遍，但与性健康相关的问题往往没有在幸存者中得到解决。本概述旨在关注妇科癌症治疗对性的影响。临床医生应将癌症治疗的性后果这一话题作为生存和服务提供的合法方面提出。对治疗的性后果和癌症存活率的更多关注可能会及时导致更大的临床认可、服务发展，最重要的是，增加对有效管理癌症护理仍然被忽视的方面的研究。